BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 18288984)

  • 1. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.
    Valverde P
    Curr Med Chem; 2008; 15(3):284-304. PubMed ID: 18288984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
    Lewiecki EM
    J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2008 Oct; 6(74):67-74; quiz 75-6. PubMed ID: 18800025
    [No Abstract]   [Full Text] [Related]  

  • 5. How to manage postmenopausal osteoporosis?
    Body JJ
    Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis.
    O'Connell MB
    J Manag Care Pharm; 2006 Jul; 12(6 Suppl A):S10-9; quiz S26-8. PubMed ID: 17269853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr; 2010 Dec; 160(21-22):586-9. PubMed ID: 21170699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualizing osteoporosis therapy.
    Silverman S; Christiansen C
    Osteoporos Int; 2012 Mar; 23(3):797-809. PubMed ID: 22218417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab for treatment of postmenopausal osteoporosis.
    Chitre M; Shechter D; Grauer A
    Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osteoporosis].
    Buck G; Perger L; Bischoff-Ferrari HA
    Praxis (Bern 1994); 2011 Jul; 100(14):821-32. PubMed ID: 21732293
    [No Abstract]   [Full Text] [Related]  

  • 14. [Innovations in the treatment of osteoporosis].
    Tsourdi E; Hofbauer LC
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
    Cremers S; Garnero P
    Drugs; 2006; 66(16):2031-58. PubMed ID: 17112299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
    Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
    Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety concerns with the long-term management of osteoporosis.
    Reginster JY; Pelousse F; Bruyère O
    Expert Opin Drug Saf; 2013 Jul; 12(4):507-22. PubMed ID: 23614635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Related Adverse Events of Osteoporosis Therapy.
    Khan M; Cheung AM; Khan AA
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):181-192. PubMed ID: 28131131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and treatment of postmenopausal osteoporosis.
    Tella SH; Gallagher JC
    J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.